Omalizumab for the treatment of severe allergic asthma in children: A tale of two.
allergy and immunology
asthma
biologic therapies
pediatrics and adolescent medicine
respiratory medicine
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
24
07
2021
revised:
14
06
2022
accepted:
14
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add-on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Children with severe asthma represent a complex heterogeneous group. This report outlines the background, management, and outcomes for two children initiated on omalizumab for severe allergic asthma in Children's Health Ireland at Tallaght. It demonstrates the difficulties faced by this cohort and the positive impact targeted biological therapy can have. Given the substantial cohort of children with asthma attending our tertiary center, it also indicates that comprehensive stepwise care can achieve adequate control in the vast majority of cases without the requirement for additional therapies.
Identifiants
pubmed: 36017116
doi: 10.1002/ccr3.6255
pii: CCR36255
pmc: PMC9393874
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e6255Informations de copyright
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
There are no conflicts of interest to declare.
Références
Lancet Respir Med. 2019 Apr;7(4):294-296
pubmed: 30824361
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):889-898
pubmed: 28689839
Pediatr Allergy Immunol. 2019 Mar;30(2):159-171
pubmed: 30444939
Curr Allergy Asthma Rep. 2018 May 9;18(5):33
pubmed: 29744661
Front Pediatr. 2018 Jun 19;6:170
pubmed: 29971223
Pediatr Allergy Immunol Pulmonol. 2018 Jun 1;31(2):44-55
pubmed: 30069422
Ann Allergy Asthma Immunol. 2019 Nov;123(5):476-482.e1
pubmed: 31382020
J Allergy Clin Immunol. 2017 May;139(5):1431-1444
pubmed: 28477722
Allergy Asthma Proc. 2017 Jul 1;38(4):250-263
pubmed: 28631599
Curr Allergy Asthma Rep. 2001 Mar;1(2):89-90
pubmed: 11899301
Expert Opin Drug Discov. 2018 Jan;13(1):51-63
pubmed: 29077521
Paediatr Drugs. 2019 Aug;21(4):215-237
pubmed: 31325115
Int J Environ Res Public Health. 2011 Aug;8(8):3192-201
pubmed: 21909300
Clin Rev Allergy Immunol. 2019 Apr;56(2):219-233
pubmed: 30206782